Ipsen SA (IPN) - Net Assets
Based on the latest financial reports, Ipsen SA (IPN) has net assets worth €4.23 Billion EUR (≈ $4.95 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€6.83 Billion ≈ $7.99 Billion USD) and total liabilities (€2.60 Billion ≈ $3.04 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Ipsen SA to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.23 Billion |
| % of Total Assets | 61.94% |
| Annual Growth Rate | 14.14% |
| 5-Year Change | 95.97% |
| 10-Year Change | 241.2% |
| Growth Volatility | 44.91 |
Ipsen SA - Net Assets Trend (2002–2024)
This chart illustrates how Ipsen SA's net assets have evolved over time, based on quarterly financial data. Also explore Ipsen SA asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Ipsen SA (2002–2024)
The table below shows the annual net assets of Ipsen SA from 2002 to 2024. For live valuation and market cap data, see IPN company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €4.18 Billion ≈ $4.89 Billion |
+9.36% |
| 2023-12-31 | €3.82 Billion ≈ $4.47 Billion |
+14.60% |
| 2022-12-31 | €3.34 Billion ≈ $3.90 Billion |
+21.88% |
| 2021-12-31 | €2.74 Billion ≈ $3.20 Billion |
+28.30% |
| 2020-12-31 | €2.13 Billion ≈ $2.49 Billion |
+21.73% |
| 2019-12-31 | €1.75 Billion ≈ $2.05 Billion |
-4.90% |
| 2018-12-31 | €1.84 Billion ≈ $2.16 Billion |
+20.02% |
| 2017-12-31 | €1.54 Billion ≈ $1.80 Billion |
+12.75% |
| 2016-12-31 | €1.36 Billion ≈ $1.59 Billion |
+11.15% |
| 2015-12-31 | €1.23 Billion ≈ $1.43 Billion |
+14.77% |
| 2014-12-31 | €1.07 Billion ≈ $1.25 Billion |
+9.67% |
| 2013-12-31 | €973.70 Million ≈ $1.14 Billion |
+5.12% |
| 2012-12-31 | €926.25 Million ≈ $1.08 Billion |
-8.78% |
| 2011-12-31 | €1.02 Billion ≈ $1.19 Billion |
-5.91% |
| 2010-12-31 | €1.08 Billion ≈ $1.26 Billion |
+9.64% |
| 2009-12-31 | €984.35 Million ≈ $1.15 Billion |
+13.34% |
| 2008-12-31 | €868.49 Million ≈ $1.02 Billion |
+8.41% |
| 2007-12-31 | €801.11 Million ≈ $936.58 Million |
+10.06% |
| 2006-12-31 | €727.90 Million ≈ $851.00 Million |
+17.20% |
| 2005-12-31 | €621.10 Million ≈ $726.13 Million |
+214.12% |
| 2004-12-31 | €197.73 Million ≈ $231.17 Million |
-36.55% |
| 2003-12-31 | €311.65 Million ≈ $364.36 Million |
+36.72% |
| 2002-12-31 | €227.95 Million ≈ $266.50 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ipsen SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 369.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €345.90 Million | 8.27% |
| Common Stock | €83.80 Million | 2.00% |
| Other Comprehensive Income | €3.74 Billion | 89.53% |
| Other Components | €8.20 Million | 0.20% |
| Total Equity | €4.18 Billion | 100.00% |
Ipsen SA Competitors by Market Cap
The table below lists competitors of Ipsen SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aramark Holdings
NYSE:ARMK
|
$10.51 Billion |
|
Skanska AB (publ)
ST:SKA-B
|
$10.51 Billion |
|
RAKUTEN GROUP SPONS.ADR 1
F:RAKA
|
$10.53 Billion |
|
The Clorox Company
NYSE:CLX
|
$10.53 Billion |
|
Trade Desk Inc
NASDAQ:TTD
|
$10.49 Billion |
|
Yangzijiang Shipbuilding (Holdings) Ltd
F:B8O
|
$10.48 Billion |
|
Texas Roadhouse Inc
NASDAQ:TXRH
|
$10.47 Billion |
|
Itaúsa - Investimentos Itaú SA
SA:ITSA3
|
$10.46 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ipsen SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,825,100,000 to 4,181,600,000, a change of 356,500,000 (9.3%).
- Net income of 345,900,000 contributed positively to equity growth.
- Dividend payments of 99,600,000 reduced retained earnings.
- Share repurchases of 36,500,000 reduced equity.
- Other comprehensive income increased equity by 661,600,000.
- Other factors decreased equity by 514,900,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €345.90 Million | +8.27% |
| Dividends Paid | €99.60 Million | -2.38% |
| Share Repurchases | €36.50 Million | -0.87% |
| Other Comprehensive Income | €661.60 Million | +15.82% |
| Other Changes | €-514.90 Million | -12.31% |
| Total Change | €- | 9.32% |
Book Value vs Market Value Analysis
This analysis compares Ipsen SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.33x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 80.16x to 3.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | €2.08 | €167.00 | x |
| 2005-12-31 | €7.38 | €167.00 | x |
| 2006-12-31 | €8.63 | €167.00 | x |
| 2007-12-31 | €9.53 | €167.00 | x |
| 2008-12-31 | €10.32 | €167.00 | x |
| 2009-12-31 | €11.66 | €167.00 | x |
| 2010-12-31 | €12.75 | €167.00 | x |
| 2011-12-31 | €12.13 | €167.00 | x |
| 2012-12-31 | €11.07 | €167.00 | x |
| 2013-12-31 | €11.68 | €167.00 | x |
| 2014-12-31 | €12.96 | €167.00 | x |
| 2015-12-31 | €14.78 | €167.00 | x |
| 2016-12-31 | €16.45 | €167.00 | x |
| 2017-12-31 | €18.37 | €167.00 | x |
| 2018-12-31 | €22.12 | €167.00 | x |
| 2019-12-31 | €20.97 | €167.00 | x |
| 2020-12-31 | €25.54 | €167.00 | x |
| 2021-12-31 | €32.81 | €167.00 | x |
| 2022-12-31 | €40.16 | €167.00 | x |
| 2023-12-31 | €45.88 | €167.00 | x |
| 2024-12-31 | €50.14 | €167.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ipsen SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.27%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.68%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.54x
- Recent ROE (8.27%) is below the historical average (17.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 32.46% | 10.56% | 1.05x | 2.92x | €50.96 Million |
| 2003 | 32.66% | 13.76% | 1.11x | 2.14x | €70.38 Million |
| 2004 | 47.41% | 11.46% | 1.17x | 3.54x | €65.50 Million |
| 2005 | 19.24% | 15.12% | 0.84x | 1.52x | €57.25 Million |
| 2006 | 19.82% | 16.71% | 0.71x | 1.67x | €71.36 Million |
| 2007 | 18.89% | 15.20% | 0.75x | 1.65x | €71.08 Million |
| 2008 | 17.03% | 14.22% | 0.66x | 1.81x | €60.98 Million |
| 2009 | 15.99% | 14.13% | 0.71x | 1.60x | €58.90 Million |
| 2010 | 8.84% | 8.14% | 0.70x | 1.56x | €-12.45 Million |
| 2011 | 0.04% | 0.03% | 0.76x | 1.61x | €-100.86 Million |
| 2012 | -3.19% | -2.31% | 0.82x | 1.69x | €-121.91 Million |
| 2013 | 15.70% | 11.90% | 0.82x | 1.61x | €55.39 Million |
| 2014 | 14.41% | 11.52% | 0.78x | 1.61x | €46.98 Million |
| 2015 | 15.53% | 12.49% | 0.78x | 1.59x | €67.65 Million |
| 2016 | 16.62% | 13.52% | 0.69x | 1.78x | €90.01 Million |
| 2017 | 17.85% | 13.54% | 0.65x | 2.01x | €119.76 Million |
| 2018 | 21.16% | 16.59% | 0.70x | 1.83x | €205.39 Million |
| 2019 | -3.14% | -2.04% | 0.63x | 2.46x | €-230.00 Million |
| 2020 | 25.71% | 20.40% | 0.62x | 2.02x | €334.88 Million |
| 2021 | 23.64% | 23.52% | 0.55x | 1.82x | €373.08 Million |
| 2022 | 19.43% | 20.55% | 0.56x | 1.68x | €314.87 Million |
| 2023 | 16.85% | 19.49% | 0.52x | 1.65x | €261.89 Million |
| 2024 | 8.27% | 9.68% | 0.56x | 1.54x | €-72.26 Million |
Industry Comparison
This section compares Ipsen SA's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $490,934,000
- Average return on equity (ROE) among peers: 2.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ipsen SA (IPN) | €4.23 Billion | 32.46% | 0.61x | $10.50 Billion |
| AB Science S.A (AB) | $-23.75 Million | 0.00% | 0.00x | $81.71 Million |
| Boiron SA (BOI) | $505.46 Million | 8.04% | 0.51x | $456.63 Million |
| Euroapi SAS (EAPI) | $1.11 Billion | -1.35% | 0.56x | $152.50 Million |
| Vetoquinol (VETO) | $371.83 Million | 5.17% | 0.74x | $1.02 Billion |
About Ipsen SA
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more